News
Delhi’s APAC Biotech bags patent for personalized immunotherapy based cancer treatment
APCEDEN – APAC’s immunotherapy product, has already been approved by the Indian FDA for treating cancer. The company has further announced it will conduct clinical trials for highly aggressive brain tumors
Moderna to expand BARDA agreement to support larger phase 3 program for Covid-19 vaccine
BARDA will extend an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Moderna’s mRNA vaccine candidate (mRNA-1273) against COVID-19.
